4//SEC Filing
Bellinger Andrew 4
Accession 0001209191-22-055063
CIK 0001840574other
Filed
Oct 31, 8:00 PM ET
Accepted
Nov 1, 5:00 PM ET
Size
8.7 KB
Accession
0001209191-22-055063
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2022-10-28−10,000→ 86,995 totalExercise: $1.48Exp: 2029-09-16→ Common Stock (10,000 underlying) - Sale
Common Stock
2022-10-28$39.90/sh−10,000$399,000→ 6,629 total - Exercise/Conversion
Common Stock
2022-10-28$1.48/sh+10,000$14,800→ 16,629 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2022.
- [F2]The remaining shares underlying this option, which was granted on September 17, 2019, vest in equal monthly installments until October 1, 2023.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0001864116
Filing Metadata
- Form type
- 4
- Filed
- Oct 31, 8:00 PM ET
- Accepted
- Nov 1, 5:00 PM ET
- Size
- 8.7 KB